Department of Patholosgy, University of Helsinki, Haartmaninkatu 3, PO Box 21, Helsinki FIN-00014, Finland.
Department of Oral and Maxillofacial Diseases, University of Helsinki, Haartmaninkatu 8, PO Box 63, Helsinki FI-00014, Finland.
Br J Cancer. 2018 Feb 20;118(4):577-586. doi: 10.1038/bjc.2017.425. Epub 2017 Nov 30.
Tumour budding has been reported as a promising prognostic marker in many cancers. This meta-analysis assessed the prognostic value of tumour budding in oral squamous cell carcinoma (OSCC).
We searched OvidMedline, PubMed, Scopus and Web of Science for articles that studied tumour budding in OSCC. We used reporting recommendations for tumour marker (REMARK) criteria to evaluate the quality of studies eligible for meta-analysis.
A total of 16 studies evaluated the prognostic value of tumour budding in OSCC. The meta-analysis showed that tumour budding was significantly associated with lymph node metastasis (odds ratio=7.08, 95% CI=1.75-28.73), disease-free survival (hazard ratio=1.83, 95% CI=1.34-2.50) and overall survival (hazard ratio=1.88, 95% CI=1.25-2.82).
Tumour budding is a simple and reliable prognostic marker for OSCC. Evaluation of tumour budding could facilitate personalised management of OSCC.
肿瘤芽殖已被报道为许多癌症中很有前途的预后标志物。本荟萃分析评估了肿瘤芽殖在口腔鳞状细胞癌(OSCC)中的预后价值。
我们在 OvidMedline、PubMed、Scopus 和 Web of Science 中搜索了研究 OSCC 中肿瘤芽殖的文章。我们使用报告肿瘤标志物(REMARK)标准的建议来评估有资格进行荟萃分析的研究的质量。
共有 16 项研究评估了肿瘤芽殖在 OSCC 中的预后价值。荟萃分析表明,肿瘤芽殖与淋巴结转移显著相关(优势比=7.08,95%CI=1.75-28.73)、无病生存率(风险比=1.83,95%CI=1.34-2.50)和总生存率(风险比=1.88,95%CI=1.25-2.82)。
肿瘤芽殖是 OSCC 的一种简单可靠的预后标志物。肿瘤芽殖的评估可以促进 OSCC 的个体化管理。